Jpmorgan Chase & CO Neurocrine Biosciences Inc Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,670,998 shares of NBIX stock, worth $334 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,670,998

Previous 1,371,186 94.79%

Holding current value

$334 Million

Previous $187 Million 57.83%

% of portfolio

0.02%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$107.22 - $153.29 $139 Million - $199 Million	1,299,812 Added 94.79%	2,670,998 $295 Million
Q4 2024 Feb 12, 2025	SELL	$111.62 - $139.44 $14.1 Million - $17.7 Million	-126,745 Reduced 8.46%	1,371,186 $187 Million
Q3 2024 Dec 26, 2024	SELL	$114.58 - $153.15 $99.1 Million - $132 Million	-864,804 Reduced 36.6%	1,497,931 $172 Million
Q3 2024 Nov 08, 2024	SELL	$114.58 - $153.15 $99.1 Million - $132 Million	-864,804 Reduced 36.6%	1,497,931 $172 Million
Q2 2024 Dec 26, 2024	BUY	$130.86 - $143.19 $113 Million - $124 Million	864,804 Added 57.73%	2,362,735 $325 Million
Q2 2024 Aug 12, 2024	BUY	$130.86 - $143.19 $8.85 Million - $9.68 Million	67,627 Added 2.95%	2,362,735 $325 Million
Q1 2024 Dec 26, 2024	BUY	$130.4 - $143.74 $104 Million - $115 Million	797,177 Added 53.22%	2,295,108 $317 Million
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $73 Million - $80.4 Million	559,565 Added 32.24%	2,295,108 $317 Million
Q4 2023 Dec 26, 2024	BUY	$106.07 - $132.76 $25.2 Million - $31.5 Million	237,612 Added 15.86%	1,735,543 $229 Million
Q4 2023 Feb 12, 2024	SELL	$106.07 - $132.76 $8.03 Million - $10 Million	-75,694 Reduced 4.18%	1,735,543 $229 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $14.2 Million - $17.6 Million	-150,637 Reduced 7.68%	1,811,237 $204 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $17.4 Million - $20.4 Million	-194,135 Reduced 9.0%	1,961,874 $185 Million
Q1 2023 May 18, 2023	BUY	$94.11 - $123.02 $10.9 Million - $14.3 Million	116,021 Added 5.69%	2,156,009 $218 Million
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $12.2 Million - $16 Million	-130,074 Reduced 5.99%	2,039,988 $206 Million
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $21.5 Million - $25.6 Million	-201,175 Reduced 8.48%	2,170,062 $259 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $57.7 Million - $67.5 Million	-626,523 Reduced 20.9%	2,371,237 $252 Million
Q2 2022 Aug 11, 2022	SELL	$75.79 - $100.07 $572,138 - $755,428	-7,549 Reduced 0.25%	2,997,760 $292 Million
Q1 2022 May 11, 2022	BUY	$72.45 - $94.81 $1.75 Million - $2.3 Million	24,210 Added 0.81%	3,005,309 $282 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $23.2 Million - $31 Million	291,601 Added 10.84%	2,981,099 $254 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $232 Million - $266 Million	2,689,498 New	2,689,498 $258 Million

Others Institutions Holding NBIX

# of Institutions

648

Shares Held

96.9M

Call Options Held

800K

Put Options Held

565K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Neurocrine Biosciences Inc Transaction History